FOR IMMEDIATE RELEASE
Vancouver, BC, Canada – March 19, 2025 – Andira Pharmaceuticals is pleased to announce the successful completion of a panel of pre-clinical safety studies as a steppingstone toward clinical trials for advanced wound care with medical device candidate SilvanexTM Flex. These standard pre-clinical studies produced positive outcomes, adding to previously published scientific studies supporting the safety of SilvanexTM antimicrobial components cannabichromene (CBC), cannabigerol (CBG) and silver.
Dana Lambert, PhD, inventor of Silvanex™ infection control technology and CEO of Andira, says, “The positive safety results were not surprising given the extensive published literature on SilvanexTM components. However, completing these rigorous studies represents a critical milestone in our product development process. We are eager to put SilvanexTM Flex to the test against standard silver wound dressings in our planned non-inferiority trial, which will be required for market approval under medical device regulations. In general, medical devices benefit from faster timelines to market approval compared to drug products.”
Andira has completed the following pre-clinical safety studies, all of which had beneficial outcomes:
- Maximum Tolerated Dose (MTD) of Single or Multiple CBC & CBG Doses: Results confirmed that both highly purified compounds were safe in a pilot study of single and repeated doses administered systemically by injection.
- ICH M7 Genotoxicity Evaluation of CBC and CBG: CBC and CBG met the criteria for ICH M7 classification as non-mutagenic.
- Human Skin Cell Biocompatibility of SilvanexTM Flex Advanced Wound Dressing: This test confirmed that Silvanex™ Flex Advanced Wound Dressing is biocompatible (non-toxic) with two human skin cell lines.
The Silvanex™ suite of products includes both medical device and drug product candidates, promising to disrupt several major healthcare markets, including the $5.44 billion surgical infection control market, the $1.17 billion silver wound dressing market, and the $952 million chlorhexidine dressing market. Silvanex™ is the world’s first triple synergy anti-infective agent with dual antibacterial and antifungal action, offering unprecedented protection against all major classes of antimicrobial resistant (AMR) “superbugs”. SilvanexTM demonstrates an 800% increase in antimicrobial efficacy compared to conventional silver ion and silver nanoparticle technologies, as shown in laboratory studies measuring bacterial and fungal kill rates. This enhanced performance stems from its triple-synergy mechanism, which rapidly eliminates pathogens while preventing further colonization and resistance.
Andira Pharmaceuticals intends to complete a panel of additional studies to further characterize the safety and biocompatibility relevant to Silvanex™ Flex and its intended use in advanced wound care applications, which includes post-surgical infection control. These future studies will include, among other things, dermal safety and biocompatibility in wound healing.
Investors and healthcare stakeholders are encouraged to follow our progress as we advance toward clinical trials and regulatory submissions. With the potential to reshape infection control, SilvanexTM technology represents a transformative opportunity in global healthcare. For more information about Andira Pharmaceuticals and SilvanexTM, please visit www.andira.ca or contact info@andira.ca.
###
About Andira Pharmaceuticals
Andira Pharmaceuticals is a cannabinoid-focused biopharmaceutical company developing innovative therapeutics and medical devices to address healthcare-associated infections (HAI) and improve the treatment of cancer. For more details, visit www.andira.ca.
Media Contact:
Nishi Whiteley
Manager of Communications
Andira Pharmaceuticals
info@andira.ca
www.andira.ca